|1.||Kahn, Jonathan: 4 articles (10/2008 - 01/2003)|
|2.||Kahn, Jonathan D: 2 articles (01/2008 - 08/2007)|
|3.||Fernandez, Alicia: 2 articles (08/2007 - 01/2007)|
|4.||Bibbins-Domingo, Kirsten: 2 articles (08/2007 - 01/2007)|
|5.||Hawkins-Taylor, Chamika: 1 article (09/2013)|
|6.||Carlson, Angeline M: 1 article (09/2013)|
|7.||de Boer, Anthonius: 1 article (01/2013)|
|8.||Maitland-van der Zee, Anke H: 1 article (01/2013)|
|9.||Sontoredjo, Timothy A A: 1 article (01/2013)|
|10.||Pena, S D J: 1 article (04/2011)|
01/01/2006 - "The African-American Heart Failure Trial was carried out in African-Americans with heart failure because prior data had demonstrated a uniquely favorable effect in this subpopulation of the drug combination in BiDil. "
01/01/2003 - "The claim that blacks die from heart failure at a rate twice that of whites is informing efforts to develop and market the drug BiDil, which is currently undergoing clinical trials to be approved by the FDA as the first drug ever specified to treat African Americans--and only African Americans--for heart failure. "
09/01/2013 - "BiDil was approved specifically as a secondary treatment for heart failure in African-American patients. "
04/01/2011 - "This was the rationale for the FDA approval of BiDil for treatment of heart failure in African Americans. "
03/01/2010 - "Recent clinical guidelines advocate the use of the isosorbide dinitrate/hydralazine combination in treatment for heart failure. "
|3.||Hypertension (High Blood Pressure)
|2.||Isosorbide Dinitrate (Isordil)
|4.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)